BioArctic AB Advances in Neurodegenerative Disease Treatments

BioArctic AB, a research-intensive biopharmaceutical company based in Stockholm, Sweden, continues to make significant strides in the development of treatments and diagnostics for neurodegenerative diseases. The company, listed on the Swedish Stock Exchange, specializes in creating disease-modifying therapies and has a strong focus on Alzheimer’s disease and Parkinson’s disease.

As of May 29, 2025, BioArctic AB’s stock closed at 182.7 SEK, with a 52-week high of 259.4 SEK on February 19, 2025, and a low of 137.7 SEK on November 7, 2024. The company boasts a market capitalization of 14.94 billion SEK and a price-to-earnings ratio of 19.77.

Key Developments in Clinical Trials

BioArctic AB’s flagship product, BAN2401, a humanized monoclonal antibody, is currently in Phase 2b clinical trials. This treatment targets toxic amyloid-beta oligomers/protofibrils in Alzheimer’s disease. Additionally, BAN2401 is in preclinical trials for treating Down’s syndrome with dementia and traumatic brain injury. A back-up version of BAN2401 is in the late preclinical phase for early Alzheimer’s disease patients.

The company is also developing AE1501, AD1502, and AD1503, which are disease-modifying treatments for prodromal and mild Alzheimer’s disease. For Parkinson’s disease, BioArctic AB is working on BAN0805, an anti-alpha-synuclein treatment. Furthermore, SC0806, a biodegradable device, is in Phase 1/2 clinical trials for complete spinal cord injuries.

Innovative Research and Collaborations

BioArctic AB is not only focused on therapeutic developments but also on advancing diagnostic methods. The company is working on imaging and biochemical biomarkers for Alzheimer’s and Parkinson’s diseases. Additionally, it is developing blood-brain-barrier technology to facilitate the passage of antibodies and other substances into the brain.

The company has established collaborations with major pharmaceutical companies, including Eisai Co., Ltd. and AbbVie Inc. It also collaborates with Brain Biomarker Solutions in Gothenburg AB to develop diagnostic methods for Alzheimer’s disease.

Company Background

Founded in 1992 and headquartered in Stockholm, Sweden, BioArctic AB was formerly known as BioArctic Neuroscience AB. The company changed its name to BioArctic AB (publ) in 2016, reflecting its broader focus beyond neuroscience.

BioArctic AB continues to be a key player in the biotechnology sector, particularly in the health care industry, with its innovative approaches to treating and diagnosing neurodegenerative diseases.